載入中
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
前收盤價
US$3.66
+US$0.08 · +2.23%
盤前
US$3.66
US$0.00 · 0.00%
10月12日 上午5:00 ET
盤中時間採用ET。市場資料可能有所延遲。
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
日內區間
目前US$3.66
52週區間
目前US$3.66
盤中時間採用ET。市場資料可能有所延遲。
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
日內區間
目前US$3.66
52週區間
目前US$3.66
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | — | — | 8.9萬 USD | — |
| 毛利 | — | — | — | −8.9萬 USD | — |
| 研究與開發 | 622.7萬 USD | 569.8萬 USD | 727.4萬 USD | 641.6萬 USD | 308.2萬 USD |
| 銷售、一般及管理費用 | 485.8萬 USD | 420.4萬 USD | 477.5萬 USD | 704.7萬 USD | 250.5萬 USD |
| 營業費用 | 1108.5萬 USD | 990.2萬 USD | 1204.9萬 USD | 1346.3萬 USD | 558.7萬 USD |
| 利息收入 | 1.3萬 USD | 2000 USD | 17.8萬 USD | 9.1萬 USD | — |
| 利息支出 | — | 31.1萬 USD | 55萬 USD | 1.5萬 USD | 115.4萬 USD |
| 折舊和攤銷 | 1.6萬 USD | 2.2萬 USD | 2.1萬 USD | 8.9萬 USD | 3000 USD |
| 營業利益 | −1108.5萬 USD | −990.2萬 USD | −1204.9萬 USD | −1355.2萬 USD | −558.7萬 USD |
| 淨利 | −1112.5萬 USD | −1021萬 USD | −1010.7萬 USD | −1234萬 USD | −404.1萬 USD |
公司資料更新於 2026年10月12日。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
